Table 1.
Baseline characteristics of study population
| Characteristic | Fimasartan/HCTZ (N=168) |
Fimasartan (N=88) |
Total (N=256) |
P-value* |
|---|---|---|---|---|
| Age (years), mean (SD) | 55.3 (9.40) | 53.4 (8.20) | 54.7 (9.10) | 0.1057a |
| Weight (kg), mean (SD) | 71.9 (9.70) | 71.3 (9.10) | 71.7 (9.50) | 0.6515a |
| Height (cm), mean (SD) | 166.8 (6.80) | 166.6 (7.90) | 166.7 (7.20) | 0.8069a |
| Sex, n (%) | 0.4607c | |||
| Male | 131 (77.98) | 65 (73.86) | 196 (76.56) | |
| Female | 37 (22.02) | 23 (26.14) | 60 (23.44) | |
| Smoking, n (%) | 0.0095c | |||
| Non-smoker | 77 (45.83) | 48 (54.55) | 125 (48.83) | |
| Past smoker | 44 (26.19) | 30 (34.09) | 74 (28.91) | |
| Smoker | 47 (27.98) | 10 (11.36) | 57 (22.27) | |
| Medication history, n (%) | 0.4739c | |||
| ACE inhibitors or ARBs | 87 (51.79) | 52 (59.09) | 139 (54.30) | |
| Calcium channel blockers | 71 (42.26) | 31 (35.23) | 102 (39.84) | |
| Beta blockers | 24 (14.29) | 17 (19.32) | 41 (16.02) | |
| Diuretics | 16 (9.52) | 9 (10.23) | 25 (9.77) | |
| Lipid modifying agents | 3 (1.79) | – | 3 (1.17) | |
| Alpha-blockers | 1 (0.60) | – | 1 (0.39) | |
| Cardiac drug | – | 1 (1.14) | 1 (0.39) | |
| Peripheral vasodilators | 1 (0.60) | – | 1 (0.39) | |
| Drinking history, n (%) | 0.0625c | |||
| Non-drinker | 39 (23.21) | 30 (34.09) | 69 (26.95) | |
| Drinker | 129 (76.79) | 58 (65.91) | 187 (73.05) | |
| Mean duration of hypertension, years (SD) | 6.20 (6.02) | 6.59 (5.84) | 6.33 (5.95) | 0.4465b |
| Baseline blood pressure, mmHg (SD) | ||||
| Diastolic | 96.8 (5.70) | 96.5 (5.40) | 0.7078a | |
| Systolic | 150.8 (12.70) | 149.4 (11.90) | 0.3994a |
Notes:
*
Difference between treatment groups by
a
two-sample t-test,
b
Wilcoxon rank-sum test, or
c
chi-square test.
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; HCTZ, hydrochlorothiazide; SD, standard deviation.